Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00072358
First received: November 4, 2003
Last updated: October 10, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):